- Associated Press•3 months ago
On a per-share basis, the Montreal-based company said it had a loss of 37 cents. The drug developer posted revenue of $242,000 in the period. In the final minutes of trading on Monday, the company's shares ...
- Capital Cube•4 months ago
Click here to see latest analysisÆterna Zentaris, Inc. reports financial results for the quarter ended December 31, 2015.We analyze the earnings along side the following peers of Æterna Zentaris, Inc. – Resverlogix Corp. and Helix BioPharma Corp. (RVX-CA and HBP-CA) that have also reported for this period.HighlightsSummary numbers: Revenues of CAD 0.14 million, Net Earnings […] (Read more...) The post Æterna Zentaris, Inc. :AEZ-CA: Earnings Analysis: Q4, 2015 By the Numbers appeared first on CapitalCube.
|52wk Range||3.77 - 26.00|
|Day's Range||4.40 - 4.50|
|Avg Vol (3m)||13,857|
As of 1:29 PM EDT. Market closed.